How does cevimeline work in the body?
Cevimeline is a muscarinic cholinergic agonist that mainly targets muscarinic acetylcholine receptors, especially the M3 subtype. By activating these receptors, it increases parasympathetic signaling to salivary glands, which raises salivary (and mucous) secretion. That is the core reason it can reduce symptoms of dry mouth in conditions where salivary output is reduced.
What does “muscarinic agonist” mean for its effects?
As a muscarinic receptor agonist, cevimeline mimics acetylcholine’s actions at muscarinic receptors. When it stimulates receptors on exocrine glands (like salivary glands), it promotes secretion. This mechanism is expected to improve xerostomia (dry mouth) and can also affect other secretory tissues, which is why cholinergic side effects can occur.
Why are M3 receptors important specifically?
M3 muscarinic receptors are strongly involved in glandular secretion. Activating M3 on salivary gland tissue helps drive saliva production, which makes M3 a key pharmacologic target for treating dry mouth symptoms.
What side effects follow from its mechanism?
Because cevimeline activates muscarinic receptors, overstimulation can lead to cholinergic-type adverse effects, such as:
- Increased sweating or flushing
- Nausea or gastrointestinal cramping/diarrhea
- Urinary frequency
- Runny nose or increased secretions
- Dizziness or blurred vision (depending on the degree of muscarinic stimulation)
These effects are consistent with its receptor-activation mechanism rather than a direct “dry mouth” effect on the mouth tissues themselves.
How is its mechanism different from “dry mouth” treatments that don’t target receptors?
Cevimeline increases secretion by stimulating muscarinic receptors. Treatments that focus on lubrication or saliva substitutes can relieve dryness without changing glandular signaling. In contrast, cevimeline aims to restore secretion by acting on the pathways that control exocrine gland output.
How does cevimeline’s action connect to clinical use in Sjögren’s-related dryness?
Sjögren’s and other salivary gland hypofunction states reduce saliva output. By activating muscarinic receptors on the remaining responsive gland tissue, cevimeline can partially restore salivary secretion, which is why it is used for symptomatic dry mouth.
Sources
No sources were provided with your request. If you share the reference text or allowed source list you want me to use, I can align the mechanism description to that material and cite it.